BioSpace News Archive

By bringing a product engineering chief in house, Izotropic will reduce long-term engineering costs associated with research and development and future planned products across the Izoview platform, including diagnostic imaging, screening, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstruction surgery.

Aztiq Pharma Partners, a private equity fund led by Róbert Wessman, announced that it has completed a US$100 million financing to purchase a newly issued share equity in Alvogen US.

The U.S. Food and Drug Administration is providing an update on its ongoing sampling and testing efforts designed to better understand the occurrence of per- and polyfluoroalkyl substances in the food supply.

The National Kidney Foundation is pleased to announce the appointment of David J. Cook, M.D., MHA, FAHA to its national Board of Directors.

Oakland Family Dental is pleased to announce that the facility is using new state-of-the-art technology during dental implant treatments to create stunning smiles, change people’s lives and improve their dental experience.

MEDIFIRST SOLUTIONS, INC. is pleased to announce naming Thomas Griffin as the Company’s CEO. In the last 25 years, Mr. Griffin has been a global entrepreneur with proven success, a seasoned advisor and investor; a well-respected aviation, finance and business development executive.

Health Canada has updated the product monographs (labels) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to describe very rare reports of myocarditis and pericarditis following vaccination.

Medical device developer Capillary Biomedical, Inc. (CapBio) has presented highly favorable clinical feasibility study results for its SteadiFlow cannula technology at this week’s American Diabetes Association (ADA) Scientific Sessions meeting.

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the initiation of a new phase I study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC) amenable to re-irradiation.

Hoag is now enrolling patients in a clinical trial to study an innovative surgical procedure that would allow surgeons to repair a patient’s mitral valve without open-heart surgery.